These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 9023272

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM, Barnes PJ, Giembycz MA.
    Cell Biochem Biophys; 1998 Nov; 29(1-2):179-201. PubMed ID: 9631245
    [Abstract] [Full Text] [Related]

  • 5. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL, Showell HJ, Fisher DA, Pazoles CJ, Watson JW, Turner CR, Cheng JB.
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [Abstract] [Full Text] [Related]

  • 6. The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline.
    Pettipher ER, Eskra JD, Labasi JM.
    Cytokine; 1997 Aug; 9(8):582-6. PubMed ID: 9245486
    [Abstract] [Full Text] [Related]

  • 7. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    Foissier L, Lonchampt M, Cogé F, Canet E.
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
    [Abstract] [Full Text] [Related]

  • 8. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S.
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [Abstract] [Full Text] [Related]

  • 9. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL, Singer M, Vargaftig BB, Chignard M.
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [Abstract] [Full Text] [Related]

  • 10. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
    Tang HF, Lu JJ, Tang JF, Zheng X, Liang YQ, Wang XF, Wang YJ, Mao LG, Chen JQ.
    Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
    [Abstract] [Full Text] [Related]

  • 11. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [Abstract] [Full Text] [Related]

  • 12. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S, Méhats C, Barnette MS, Ferré F, Cabrol D, Leroy MJ.
    Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line.
    Delgado M, Fernández-Alfonso MS, Fuentes A.
    Arch Dermatol Res; 2002 Jul; 294(4):190-7. PubMed ID: 12111350
    [Abstract] [Full Text] [Related]

  • 15. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
    Yamamoto S, Sugahara S, Naito R, Ichikawa A, Ikeda K, Yamada T, Shimizu Y.
    Eur J Pharmacol; 2006 Jul 10; 541(1-2):106-14. PubMed ID: 16780833
    [Abstract] [Full Text] [Related]

  • 16. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor.
    Wright KF, Turner CR, Jayasinghe-Beck R, Cohen VL, Cheng JB, Watson JW.
    Can J Physiol Pharmacol; 1997 Aug 10; 75(8):1001-8. PubMed ID: 9360015
    [Abstract] [Full Text] [Related]

  • 17. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE, Asker ME, Ali SI, el-Fattah TM.
    J Pharm Pharmacol; 2004 Jun 10; 56(6):757-68. PubMed ID: 15231041
    [Abstract] [Full Text] [Related]

  • 18. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S.
    Eur J Immunol; 1995 Jan 10; 25(1):147-53. PubMed ID: 7843225
    [Abstract] [Full Text] [Related]

  • 19. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
    Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, Hebb AL, Owens T, Robertson GS.
    J Pharmacol Exp Ther; 2006 Oct 10; 319(1):63-72. PubMed ID: 16809479
    [Abstract] [Full Text] [Related]

  • 20. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, Huang Z, Nicholson DW, Mancini JA.
    J Pharmacol Exp Ther; 2004 Aug 10; 310(2):752-60. PubMed ID: 15082748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.